Samil Pharmaceutical Largest Shareholder CEO Seungbeom Heo Increases Stake from 25.83% to 25.96% via Open Market Purchases and Gift
Samil Pharmaceutical's largest shareholder and CEO Seungbeom Heo increased his stake to 25.96% through open market purchases and a gift from a family member.
As of the report date July 21 2026, holdings increased by 28,275 shares representing 0.13% of total outstanding shares compared to the previous report.
He received 200,000 shares as a gift from related party Kang Heo and purchased 210,000 shares in the open market, resulting in a total increase of approximately 410,000 shares.
Stock pledge agreements for three special related parties including Junbeom Heo, Kang Heo, and Hyeyeon Lee have been extended or newly entered, covering 797,392 shares or about 3.68% of total shares.
The pledged shares represent about 14% of the group's total holdings, posing a risk of margin calls or forced sale if the stock price declines.
The stated purpose of holding is to maintain management influence; no specific plans currently exist but decisions will be made considering shareholder interests.
[AI Summary]The slight increase in the largest shareholder's stake is positive for management stability, but the significant pledge ratio introduces downside risk from price volatility. No capital changes or dividends reported, neutral for near-term stock price.